Spots Global Cancer Trial Database for Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan
Official Title: Phase I Clinical and Pharmacokinetic Trial of Intra-Peritoneal Irinotecan
Study ID: NCT00183859
Interventions
Study Description
Brief Summary: This is a research study for patients that have an advanced cancer that is confined mostly to the abdominal cavity and have failed treatment with conventional therapy, or for which no standard treatment exists. The purpose of this study is to determine the dose of a chemotherapy drug (called irinotecan) that can be administered safely into the abdominal cavity. We also wish to identify the side effects of irinotecan when it is administered directly into the abdomen. In this study, we will also determine the levels of irinotecan in the blood and in the abdominal cavity. Irinotecan is a chemotherapy drug that can decrease the size of several different tumors. It is approved by the FDA for the treatment of colon cancer. It appears that some other chemotherapy drugs are more effective and may have less side effects when they are administered directly into the abdomen.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
U.S.C. / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Contact Details
Name: Syma Iqbal, M.D.
Affiliation: U.S.C. / Norris Comprehensive Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
